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The use of charged particle therapy in cancer treatment is growing rapidly, in large part 
because the exquisite dose localization of charged particles allows for higher radiation 
doses to be given to tumor tissue while normal tissues are exposed to lower doses 
and decreased volumes of normal tissues are irradiated. In addition, charged particles 
heavier than protons have substantial potential clinical advantages because of their addi-
tional biological effects, including greater cell killing effectiveness, decreased radiation 
resistance of hypoxic cells in tumors, and reduced cell cycle dependence of radiation 
response. These biological advantages depend on many factors, such as endpoint, 
cell or tissue type, dose, dose rate or fractionation, charged particle type and energy, 
and oxygen concentration. This review summarizes the unique biological advantages of 
charged particle therapy and highlights recent research and areas of particular research 
needs, such as quantification of relative biological effectiveness (RBE) for various tumor 
types and radiation qualities, role of genetic background of tumor cells in determining 
response to charged particles, sensitivity of cancer stem-like cells to charged particles, 
role of charged particles in tumors with hypoxic fractions, and importance of fraction-
ation, including use of hypofractionation, with charged particles.
Keywords: charged particles, proton therapy, carbon-ion therapy, relative biological effectiveness, clustered DNA 
damage, cancer stem cells, hypoxic radioresistance, altered fractionation
iNTRODUCTiON
Radiation therapy is a mainstay of cancer treatment, being a common and effective therapy for 
both curative and palliative treatment of cancer patients. In the last few decades, there has been 
increasing use of charged particles in radiation therapy. Protons were first proposed for use in cancer 
therapy by Robert R. Wilson (1), and the number of patients treated with protons has increased 
dramatically in recent years to a total of over 100,000 patients now treated worldwide (http://www.
ptcog.ch/index.php/facilities-in-operation). Radiation treatment of cancer with helium ions began 
at Berkeley in the late 1950s and was expanded to heavier ions in the 1970s [see a review of the 
history of charged particles by Skarsgard (2)]. Much of the emphasis has been on carbon ions, with 
most patients treated in Japan and now totaling over 10,000 patients treated worldwide. The major 
clinical advantage of protons and heavier charged particles, such as carbon, comes from physics: the 
Bragg curve provides excellent radiation dose distributions [see reviews in Ref. (3, 4)]. In addition, 
heavier ions, e.g., carbon, offer the potential of additional biological gains such as increased relative 
biological effectiveness (RBE) and decreased oxygen enhancement ratio (OER) due to their higher 
February 2016 | Volume 6 | Article 232
Held et al. Charged Particles in Tumor Cells
Frontiers in Oncology | www.frontiersin.org
linear energy transfer (LET) in the Bragg peak region, where the 
tumor is located [reviewed, e.g., in Ref. (3, 5, 6)].
Despite the often-made assumption that the RBE for tumor 
cells is higher than that for normal cells irradiated under identical 
conditions, there is only a limited amount of experimental in vitro 
data that support that assertion (3). However, there have been 
interesting recent research findings on the differential DNA repair 
pathways of cancer cells after particle versus photon irradiation, 
new studies on the effects of charged particles on cancer stem 
cells, and increasing questions about different responses of tumor 
and normal cells to hypofractionation, especially with charged 
particle irradiations, suggest that there may be novel ways to 
take advantage of differences in characteristics of tumor cells 
from normal cells to improve or better tailor the use of charged 
particles in cancer therapy. This review will discuss these issues, 
with emphasis on data on responses of human tumor cells, largely 
based on in vitro findings. As discussed in more detail below, RBE 
is a complex quantity, depending on physical parameters, such as 
particle type and energy, dose and LET, and biological param-
eters, including cell/tissue type, cell cycle phase, oxygen level, 
and endpoint. In vitro assays have limitations compared to in vivo 
studies and the clinical situation due to lack of 3D architecture 
and microenvironmental context, including interactions among 
various cell types, vasculature, and immune system influences. 
Nevertheless, for studies of RBE, in  vitro assays are critical for 
systematic testing and characterization of effects of various ions, 
elucidation of DNA damage pathways, and the importance of 
DNA repair processes and other genetic factors. Furthermore, 
in  vitro studies provide experimental tests for validation of 
biophysical models, e.g., the local effects model (LEM), prior to 
clinical application (7), and yield insight on systematic variations 
in RBE relevant to clinical use (8, 9).
In this review, we start with brief overview sections on the 
unique biological advantages of charged particle therapy and 
DNA damage responses that may be important for particle 
therapy. That introduction is followed by consideration of recent 
findings on RBEs in human tumor cells, including discussion of 
the possible roles of genetic factors on RBE, then discussions of 
new findings on cancer stem cells, hypoxia, and fractionation. In 
particular, we stress approaches to use the increasing knowledge 
of the properties of tumors and tumor cells to better advantage 
when using charged particles in cancer therapy.
AN OveRview OF THe UNiQUe 
BiOLOGiCAL ADvANTAGeS OF 
CHARGeD PARTiCLe THeRAPY
A number of reviews [e.g., in Ref. (3–5)] have discussed the sub-
stantial dose distribution advantages of charged particles where, 
as a result of the Bragg peak, normal tissues can be spared by limit-
ing dose to them, while maximum dose is deposited in the tumor. 
Heavier ions, such as carbon, have an additional dose distribution 
advantage over protons because of their reduced lateral scattering 
compared to protons. However, the major potential advantage of 
heavier ions in tumor irradiations is their enhanced biological 
effects, which include increased cell killing, decreased protection 
by hypoxia, decreased effect of fractionation, and decreased cell 
cycle dependence. The biological effectiveness of cell killing by 
higher LET radiations is usually quantified by use of RBE, the ratio 
of the dose of low-LET radiation (usually X-rays or gamma-rays) 
to dose of high-LET radiation (e.g., charged particle) for the same 
biological effect. Many in vitro studies over the years have shown 
the bell-shaped dependence of RBE for cell killing on LET (6, 
10–12) wherein RBE increases with LET to a maximum at about 
30–150 keV/μm, then decreases at higher LET. The LET value at 
which the RBE is maximal depends on the individual ion species, 
with the peak at higher LET with increasing atomic number of 
the ions (2). Furthermore, it has also long been recognized that 
there is great variation in the absolute values of RBE because RBE 
depends on numerous factors, including particle type and energy, 
cell type, experimental endpoint, cell cycle phase, dose and dose 
rate, oxygenation status, culture conditions, etc. (6, 7, 11).
The increased biological effectiveness of radiations with 
increasing LET lies in the physical dose distribution of the energy 
of the particles on the micro, and even nano, scale as they traverse 
matter, the clustering of DNA damages that results from the par-
ticle tracks and the increased difficulty cells have in accurately 
repairing the clustered damage (13–16). As energetic charged 
particles traverse matter, e.g., cells and tissues of organisms, their 
electronic interactions with atoms and molecules, mostly through 
inelastic collisions with atomic electrons, create a path, or track 
of ionizations before they run out of energy at a finite range, 
the Bragg peak. The tracks of heavy charged particles are fairly 
straight, but the electrons ejected from atoms along the track, 
being much lighter, follow paths that are quite tortuous, with 
their ranges depend on the energy they acquired when ejected. 
LET is a measure of the energy imparted to matter by the passage 
of an ionizing particle. Along the path of a charged particle, the 
three-dimensional distribution of energy depositions, which 
cause ionizations and excitations, is called the track structure. 
For low-LET sparsely ionizing radiations, there are relatively long 
distances between the energy depositions except at track ends, 
but with increasing LET, the ionizations along the track become 
denser and there is lateral spread of the track due to delta-ray 
electrons, the spectrum of which is determined by the velocity of 
the heavy charged particle.
If the ionizations from radiation were randomly distributed in 
cells, the consequences of those energy depositions would likely 
be minimal, but the non-randomness of the energy depositions 
accounts for the increased effectiveness of ionizing radiation (14, 
17, 18). The clustering of ionizations along radiation tracks occurs 
on the same scale as the diameter of a DNA molecule and nucle-
osomes such that if a track traverses DNA it can effectively create 
clustered DNA damages, such as double-strand breaks (DSBs), 
clusters of two or more base damages, or clusters of single-strand 
breaks with base damages. As LET of radiation increases, the clus-
tering becomes more complex, creating, for example, a complex 
DSB where the break is associated with additional damages, such 
as base changes or single-strand breaks. Both the proportion and 
degree of complexity increase with high-LET radiations (19). 
A number of studies have shown that the complex DNA dam-
ages produced by high-LET radiations are repaired less rapidly, 
less accurately, and less completely than damages from low-LET 
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photons [reviewed recently in Ref. (20, 21)]. Additionally, it is 
important to bear in mind that track structure has biological 
relevance not only at the level of DNA damage but also at higher 
levels of chromatin organization (17): a single high-LET particle 
track passing through a cell nucleus may cause correlated dam-
ages through chromatin structures, such as chromatin fibers, or 
in adjacent chromosome territories via a string of DSBs along its 
path, and these correlated damages may result in complex chro-
mosome aberrations. Altogether, the net effect is that complex 
DNA damages resulting from the greater clustering of ionizations 
with increasing LET of radiation increases the production of all 
chromosome aberrations, simple as well as complex.
The increased DNA damage complexity and decreased 
repair accuracy with radiations of increasing LET not only 
cause increased cell killing but also result in decreased cell cycle 
dependence of that killing and play a factor in the decrease in 
OER. Cells exposed to low-LET radiation show increased resist-
ance when irradiated in late S-phase and increased sensitivity 
when irradiated in M-phase (22). This fluctuation through the 
cell cycle decreases with higher LET radiations. However, since 
in many tumors, the majority of cells are not in the radiation-
resistant phases, this effect on treatment outcome in irradiated 
tumors is likely to be modest (3). The importance of the decreased 
OER with high LET is discussed below.
Although there has been increasing interest in recent years 
in the so-called “non-targeted” effects of radiation, including 
bystander effects and genomic instability in progeny of irradi-
ated cells [for recent reviews, see Ref. (23, 24)], it remains far 
from clear whether non-targeted effects are similar or different 
after irradiation with photons versus charged particles (25–27). 
Furthermore, the role of non-targeted effects or intercellular 
signaling in response of tumors to radiation remains under 
investigation (28, 29), with very little work having been done with 
charged particles. This review is limited to discussion of targeted 
effects of charge particles.
OveRview OF DNA DAMAGe 
ReSPONSeS ReLevANT TO 
CHARGeD PARTiCLe BiOLOGY
Central to any consideration of the effects of charged particles 
on cells and tissues must be DNA damage response processes. 
Cells have two main pathways for the repair of radiation-induced 
DSBs: non-homologous end-joining (NHEJ) and homologous 
recombination (HR) (30–32). NHEJ is active throughout the 
cell cycle and is responsible for the repair of most DSBs in cells. 
NHEJ involves the initial binding of the Ku70/Ku80 heterodimer, 
recruitment of DNA–PKcs and eventual ligation of the DNA ends 
by XRCC4–DNA Ligase IV. However, NHEJ is an error-prone 
repair, and the quality of its repair processes can decrease with 
increasing levels of DNA damage. HR is active primarily during 
the S/G2 phases of the cell cycle, when a homologous DNA region 
is available, and generally results in the preservation of the origi-
nal DNA sequence. HR involves DSB recognition by the MRN 
complex (Mre11, Rad50, Nbs1), 3′–5′ DNA resection, DNA 
stabilization by replication protein A (RPA), Rad51-mediated 
formation of Holliday junctions, and ultimately resolution of the 
Holliday junction (31, 33). HR is also involved in the repair and 
restart of collapsed DNA replication forks (34). At the forks, the 
BRCA1/2-dependent HR pathway converges with the Fanconi 
anemia (FA) pathway to resolve the damage (35). It has been sug-
gested that unrepaired clustered DNA damages that collide with 
replication forks in cells in S-phase require HR for DNA repair 
and replication restart (36, 37).
It also has been reported that the end-resection activity in cells 
in the G1 phase may promote micro-homology-mediated end 
joining (MMEJ) to repair DSBs that cannot be repaired efficiently 
by NHEJ (38). However, it is unknown how much the activation 
of HR and MMEJ pathways contribute to escaping cell death in 
high-LET-irradiated cells. Recently, we showed that targeting and 
suppressing NHEJ repair yields a high radiosensitivity in cells 
exposed to carbon-ion beams when compared to the suppression 
of HR repair (39).
RBes OF CHARGeD PARTiCLeS 
iN HUMAN TUMOR CeLLS
Experimental studies to determine RBEs have been conducted for 
many years, with the majority using clonogenic cell survival as 
the endpoint. It has been felt that lack of clonogenicity is a highly 
relevant indicator of the efficacy of radiation and its modification 
because eradication of tumor cells is needed to cure tumors (22). In 
fact, the shape of curves of tumor control probability, as detected 
in a clinical context, can be explained from the random nature of 
tumor cell killing by radiation and the need to kill every cell, as 
a single cell may give rise to tumor regrowth (22). Furthermore, 
RBE values, measured or predicted by computer models, are used 
in clinical treatment planning approaches, which are continually 
being updated [e.g., Ref. (40, 41)].
It has been argued recently that further studies measuring RBE 
values may be of limited usefulness because they will have little 
impact on reducing the uncertainties in ion beam therapy (4, 6). 
However, determinations of RBEs can help guide understanding 
of mechanistic underpinnings to the increased effectiveness of 
higher LET radiations and, thus, may lead to better identification, 
based on genetic profiles or biomarker evaluation, of patients’ 
tumors that may benefit most from charged particle therapy.
Shifting the Paradigm of a Generic 
RBe for Clinical Proton Beam Therapy
Clinical proton beam therapy has been based on the use of a 
generic RBE of ~1.1 at the center of the spread-out Bragg peak 
(SOBP) for cancer as well as for normal tissues (8). This RBE value 
represents an average of a wide range of experimental data in vitro 
and in vivo and has been intended to be a conservative estimate 
(8, 42). However, there is now a growing appreciation that the 
use of a generic value ignores RBE variations that may result, for 
example, from the heterogeneity of human cancers, LET varia-
tions along the SOBP, or the particular clinical endpoint under 
consideration (42–46). In this section, we will focus primarily on 
recent data that indicate a dependence of RBE on certain DNA 
repair defects, with the implication being that proton therapy may 
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have a biological advantage in human tumors that harbor such 
defects.
There exists very little experimental data on RBE variations in 
human cancers. In a 2002 review by Paganetti and colleagues (8), 
the average RBE at the mid-SOBP was estimated as ~1.2 in vitro 
and ~1.1 in vivo. However, most of the 20 cell lines considered 
in that analysis were of rodent origin resulting in a somewhat 
higher in  vitro RBE. Only seven human cancer cell lines were 
included. There is growing evidence for considerable genomic 
heterogeneity across cancers even of the same type and histology, 
and it is increasingly appreciated that much of the variations 
in treatment sensitivity observed clinically are due to genomic 
heterogeneity, which may include alterations of DNA repair 
pathways (47–49). Therefore, it is highly doubtful that small 
numbers of non-representative cell lines are adequate pre-clinical 
models for assessing clinically relevant variations in RBE values 
in human cancers. In a recent screen of 17 lung cancer cell lines, 
RBE estimates at the mid-SOBP of a clinical beam relative to 
Co60 photons [Co60 equivalent (Eq)] ranged from 0.93 to 1.77 
and 1.09 to 1.48 for clonogenic survival fractions of 0.5 and 0.1, 
respectively (44). In five cell lines (29%), the RBE increase was 
statistically different from 1.1. Furthermore, in at least three of 
these cell lines, the RBE increase correlated with defects in the 
so-called FA/BRCA pathway of DNA repair, and this observa-
tion was confirmed in several isogenic cell line models. The FA/
BRCA pathway is critical for the maintenance and repair of DNA 
replication forks [reviewed in Ref. (34, 50)]. Inactivation of any 
of the FA/BRCA genes has been known to result in hypersensi-
tivity to a variety of anti-cancer agents. However, apart from an 
involvement of the RAD51 recombinase (FANCR) in the cellular 
response to proton radiation (43, 51), the importance of the FA/
BRCA genes for the repair of proton damage to DNA had been 
unknown. These observations are clinically significant because 
genetic or epigenetic defects in the FA/BRCA pathway have been 
found in large subsets of human cancers (34).
What are the mechanisms through which the FA/BRCA 
pathway acts on proton damage? For low-LET radiation, which 
includes X-rays and protons, it has been estimated that 20–40% 
of the initial damage is clustered, and the majority of clustered 
damage is present as non-DSB damage (52, 53). Proton radia-
tion causes slightly more complex clustered DNA damages than 
photons, which is a reflection of the different LET values, i.e., 
~2.5 keV/μm for protons at mid-SOBP versus ~0.3–2.0 keV/μm 
for different photon radiations. DNA repair-proficient tumor 
cells and normal cells remove these damages almost equally well, 
consistent with a proton RBE of 1.1 (Co60Eq). Because the FA 
genes are specifically involved in replication fork maintenance 
and repair, it can be inferred that the RBE increase that is seen 
with defects in this pathway results from impaired repair of forks 
that collide with clustered proton damages. The requirement for 
the FA/BRCA pathway is greater for proton damage compared 
to damage caused by, for example, X-rays, even though the RBE 
(Co60Eq) and LET of these two radiation modalities are almost 
identical [RBE(Co60) ~1.1 and LET = 2.0–2.5 keV/μm]. This is 
illustrated in Figure  1A. Proton-irradiated FA/BRCA-defective 
cells will accumulate greater numbers of DNA DSB in S-phase and 
subsequently G2-phase than X-irradiated cells, as has been shown 
experimentally (44) (Willers et al., unpublished). Interestingly, an 
increase in the size of DSB-associated foci persisting after proton 
irradiation has been observed (44), likely signifying unrepaired 
clustered damages (Figure  1A). It has been proposed that 
these DSB foci could serve as predictive biomarkers to identify 
cancers that may be more susceptible to proton beam therapy 
(44). Alternatively, genetic or epigenetic defects in the FA/BRCA 
pathway could be detected through genomics techniques in order 
to identify patients for proton therapy. This approach will require 
a more detailed knowledge of the genes involved in the cellular 
response to clustered proton damages. The available data indicate 
that functional loss of any of several key genes in the FA/BRCA 
pathway will increase the RBE, with the best current estimate 
being an average RBE of 1.33 (95% confidence limits, 1.25–1.41) at 
mid-SOBP as shown in Figure 1B. This is a conservative estimate 
derived at a surviving fraction of 0.1. For 0.5 survival fraction, 
which is more applicable to fraction sizes of 2 Gy as used in the 
clinic and which overlaps with the shoulder of the survival curves, 
the RBE values of the most proton-sensitive cell lines tended to be 
even higher than for 0.1 survival fraction. For example, the five 
most sensitive lung cancer cell lines in the report by Liu et al. (44) 
had an average RBE of 1.30 (range, 1.22–1.48) and 1.46 (range, 
1.31–1.77) at survival fractions of 0.1 and 0.5, respectively.
In conclusion, these recent pre-clinical data strongly sug-
gest inter-tumoral heterogeneity of proton RBE that may yield 
opportunities to identify proton susceptible tumors in the clinic 
within the next few years. This “New Biology” of protons in 
cancer coupled with the increasing knowledge of RBE variations 
as a function of physical proton beam parameters in both cancers 
and normal tissues is expected to shift the paradigm of a generic 
proton RBE to a variable RBE.
RBe Determinations with Heavy Charged 
Particles
The proton studies just described provide a possible DNA repair 
capacity-based explanation for some of the variation seen in 
proton RBE values at a given LET. Could a similar finding 
apply to human tumors exposed to high-LET charged particles? 
Unfortunately, no single study with a substantial number of cell 
lines has yet been done for any heavy ion, although many small 
studies with a few cell lines each have been performed. Some 
large compilations of cell survival RBE values for many cell types, 
endpoints and radiation qualities have been published recently (7, 
54, 55), and the composite data clearly show that RBEs depend 
on LET, endpoint, ion, etc. In this section, we focus on analysis of 
RBE values for human tumor cells exposed to ions heavier than 
protons. Published papers that describe the cell survival RBE of 
human tumor cells have been searched by using PubMed; many 
of these papers are included in the compilations mentioned. 
A total of 430 RBE values were collected from 36 published papers 
(56–91). When authors provided RBE values along with dose–
response data, those values were used. In cases where authors 
showed dose–response curves but did not cite any RBE value, 
an isoeffect line was drawn in the dose–response curves to read 
corresponding doses of ions and reference photons. As reference 
beam, 30 papers used X-rays and 6 papers used gamma-rays. 
FiGURe 1 | A “New Biology” of proton beam therapy. (A) Illustration of how FA/BRCA defects may sensitize cells to proton irradiation. Left, clustered DNA 
damages after equal physical doses of X-rays and mid-SOBP protons are slightly different despite similar LET (2–2.5 keV/μm) and identical RBE in repair-proficient 
cells (~1.1). In the presence of a FA/BRCA defect that affects the repair of replication forks encountering clustered damages, there will be greater unrepaired 
damage after proton-irradiation, as marked by an increased number and relative size of repair-related protein accumulations of DNA double-strand break markers. 
Representative immunofluorescence microscopy images showing nucleus (DAPI) and 53BP1 foci (green) in FANCD2-mutant cells are shown on the right. 
(B) Summary of RBE estimates relative to Co60 photons as a function of defects in the FA/BRCA pathway (44, 45). Other, taken from unpublished data (Willers 
et al.); CoEq, Co60 equivalent; SF, surviving fraction; CL, confidence limits.
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For the analyses here, the biological differences in effect between 
X-rays and gamma-rays were not considered.
Endpoint
Endpoint is one of the major factors, which affects the values of 
RBE (7, 54, 55, 92). The RBE data as a function of LET sorted 
by endpoint are shown in Figures 2 and 3. All papers included 
in Figure  2 presented RBE values for colony formation after 
exposure to a range of single doses. Within a total of 363 RBE 
values, 295 values in 31 papers were calculated using an isoeffect 
dose of 10% survival (D10). The other values that were calcu-
lated included D0, D30, D50, D75, ratio of alpha parameters, or 
isodose effectiveness. The RBE values for D10 ranged from 1.03 to 
4.99, showing the “classic” increase in RBE with LET followed by 
a decrease at higher LET (22) although the range in RBE values at 
any given LET is substantial in many cases. The RBE values based 
on D0, D30, D50, and D75 also showed considerable variation at 
any given LET, but, as expected, there was a trend for higher RBE 
values at higher levels of survival (22). Some of the highest RBE 
values were derived using the alpha ratio; this, too, is consistent 
with higher RBEs at higher survival, since alpha ratios would tend 
to be derived based on high survival data.
The other endpoint that tends to show high RBE values is 
apoptosis (Figure 3B). This is consistent with the observations 
that most solid tumor cell lines are resistant to X-ray-induced 
apoptosis (93) and that apoptosis may be characterized by the 
alpha-component of the cell survival curve [reviewed, e.g., in Ref. 
(94)]. In a recent review on proton radiobiology, Tommasino and 
Durante (95) pointed out that there is a general tendency for an 
increased apoptotic response with increasing LET and that tumor 
cells resistant to photon-induced apoptosis may have apoptosis 
triggered by an alternative pathway by protons, a suggestion 
that could likely extend to heavier charged particles. However, it 
should also be pointed out that several groups, including Brown 
and colleagues (96), have demonstrated that apoptosis induction 
can be markedly affected by tumor cell genetics and the overall 
level of cell killing as determined in a clonogenic assay in vitro 
may not correlate well with apoptosis induction [also reviewed 
in Ref. (94)].
Two papers reported RBE values calculated for residual 
unrepaired chromatin breaks using premature chromosome 
condensation (PCC) (Figure 3A), with the paper by Suzuki et al. 
using primary cells obtained by biopsy from patients (67, 72). 
Authors of both studies noted the good correlation between their 
data on residual chromatin breaks as measured using the PCC 
technique and colony formation, and concluded that the PCC 
technique was a potential predictive assay of tumor response 
to ion therapy. Information on correlation of chromatin breaks 
using PCC with DNA repair protein foci formation and/or FA/
BRCA pathway status, as discussed above for potential use with 
proton therapy patients, would be helpful for assessment of pos-
sible predictive assays.
Ion
The data on RBE values calculated using D10 and sorted by ions 
are shown in Figure 4. A total of 29 papers reported 247 RBE 
values for carbon-ion beam, whereas there were 21 RBE values 
for helium ions in 3 papers, 24 values for neon ion in 2 papers, 
6 values for boron ions in 1 paper, 6 values for silicon beam in 2 
papers, 5 values for iron beam in 3 papers, 2 values for nitrogen 
beam in one paper, and 3 values for argon beam in 2 papers. The 
RBE values showed substantial variation at any given LET, inde-
pendent of ion species used, but in all cases the RBE increased 
with LET to a maximum then decreased at high-LET levels. It 
is well known that the RBE values of carbon ions peak around 
an LET of 100 keV/μm (7, 54, 55, 92). The other ion beams had 
peaks between LETs of 100 and 200 keV/μm, with a trend toward 
a maximum at higher LET with heavier ions.
FiGURe 2 | RBe versus LeT for human tumor cell lines for various endpoints. RBE values are all based on colony formation assays. (A) RBE values 
calculated as the ratio of isoeffect doses at 10% survival (D10). (B) RBE values calculated as ratios of doses for D0, D30, D50, and D75. D0 was calculated by fitting 
the survival curve to the single-hit multi-target (SHMT) model: S/S0 = 1 − (1 − e−D/D0)n. (C) RBE values calculated as the ratio of doses at the level of photon doses 
of 2 Gy (SF2) or 3 Gy (SF3). (D) RBE values calculated as the ratios of the alpha parameters of survival curves.
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Furusawa et  al. (59) exposed human salivary gland tumor 
cells to carbon, neon, and helium ion beams and calculated the 
RBE values of each beam. They showed that the RBE values for 
helium ions were higher than those for the other ions, which 
seems unexpected. This finding deserves more investigation as 
there is some interest in development of helium ion beams for 
cancer therapy since they have less lateral dose than protons 
(i.e., a better dose distribution) (97), which might make their use 
particularly relevant in children. Furthermore, in their report, 
Furusawa et al. show that the peaks of the RBE values shifted to 
higher LET values with increasing atomic number, an observa-
tion that had been made earlier on the basis of work by a number 
of authors [e.g., Ref. (11, 98, 99)] as reviewed by Skarsgard (2). 
Such findings deserve emphasis as they highlight the fact that 
LET is not adequate as the sole descriptor of energy deposition in 
cells and tissues, but that ion track structure, the nanometer scale 
distribution of energy, must be considered when evaluating bio-
logical effects. In this context, it is interesting to note that NASA’s 
model for calculating risk of radiation-induced cancer from space 
radiation takes into account track structure of heavy ions rather 
than simply LET (100). In a clinical context in heavy ion therapy, 
the LEM, which is used for RBE prediction, also provides particle 
species and LET-specific RBE values that are then propagated, 
using a treatment planning system, to a representative RBE value 
at each position in the irradiated field (9, 101), a process needed 
because ion fragmentation produces a mixed radiation field.
With regard to ions, it is worth pointing out that we did not 
include data with oxygen ions in Figure 4 because we found only 
one study using oxygen ions, and that work used only a single 
LET (87). That work reported that for four human hepatocellular 
carcinoma cell lines irradiated in the SOPB of oxygen ions with a 
mean energy of 154 MeV/u (LET of 146 keV/μm), the clonogenic 
RBE10 values ranged from 1.9 to 3.1, with the values not being 
significantly different from those obtained in the same study 
using 130 MeV/u carbon ions (LET of 112 keV/μm). However, 
this study is noteworthy because of the current interest in using 
FiGURe 3 | RBe versus LeT for human tumor cell lines for chromatin breaks and apoptosis. (A) is from data on unrejoined chromatin breaks in cells after 
premature chromosome condensation (PCC). Residual unrejoined chromatin breaks were detected using Giemsa staining in cells after chromatin condensation. 
(B) is RBE values for apoptosis.
February 2016 | Volume 6 | Article 237
Held et al. Charged Particles in Tumor Cells
Frontiers in Oncology | www.frontiersin.org
oxygen ions, with their lower OER, in treating tumors with large 
hypoxic fractions (102).
Type of Tumor Cells
The data on RBE values as a function of LET for carbon-ion 
beam only, calculated using D10 and sorted by tumor type, 
are shown in Figure  5. Figure  6 shows a subset of the data 
separated out by adenocarcinoma and squamous cell carci-
noma. The graphs show data only for LET  <  100  keV/μm. 
The number of data points, or cell lines, varies greatly with 
tumor type. Generally, the brain tumors (composite slope of 
0.018) and adenocarcinomas (composite slope of 0.018) appear 
to have lower slopes for the RBE versus LET curves than do 
squamous cell carcinomas (composite slope of 0.024 or higher). 
It should be noted, however, that data from Suzuki et al. (71) 
for cervical cancer included in the squamous cell carcinoma 
graph were derived from primary cultured cells from biopsies 
from patients, the only data from primary cultures included in 
this analysis. These primary culture data appear to have lower 
slopes than the other squamous cell data, although it should also 
be noted that the steeper slopes for the established squamous 
carcinoma cell lines are determined by only four data points at 
high-LET values. Thus, it is not possible to determine whether 
there is a systematic difference between primary squamous cell 
cultures compared to established tumor cell lines or between 
squamous cell carcinomas and adenocarcinomas. It is not clear 
from clinical data with carbon ions whether a difference exists 
between sensitivity of squamous tumors and adenocarcinomas, 
suggesting an area for further in vitro, in vivo, and/or clinical 
study. For comparison, it can be pointed out that in a similar 
analysis approach, Ando (54) found that the RBE versus LET 
plot for cultured human fibroblasts had a slope of 0.027, which 
the author noted was steeper than the composite slope for the 
human tumor data he analyzed.
The RBE values for the pancreas cancer cells are the lowest 
in all the data (64). The slope of the graph of pancreas is 0.0084, 
which is gentler than the others. This might suggest that pan-
creatic cancer would not be a good candidate for carbon-ion 
therapy, yet clinical trials of carbon ions for pancreas cancer in 
Japan have shown promising results (4, 103). The clinical results 
may reflect properties of the human tumors in situ, such as high 
hypoxia, radioresistance (high cancer stem cell component?), and 
anatomic location, that might not be evident in studies of isolated 
tumor cells.
It is noteworthy that there are few tumor cell data on RBE 
values with charged particles for prostate cancer or bone and 
soft tissue cancers, which are the two cancer types with the most 
patients treated to-date with carbon ions at NIRS in Japan (103). 
Furthermore, we found no experimental RBE data for human cell 
lines of mucosal malignant melanoma, adenoid cystic carcinoma, 
or rectal carcinoma, which are all being treated with carbon ions 
at NIRS with favorable outcomes (103).
D10 has been used as the parameter for calculating RBE values 
in this analysis by tumor type (Figures 5 and 6) because that is 
the parameter most frequently reported in the literature. However, 
the use of D10 may have minimized the ability to see differences 
between tumor cell types, resulting in the relatively similar values of 
the slopes of the RBE versus LET curves for the various tumor cells. 
Generally, inherent photon radiosensitivity differences between 
cell types become most evident at high and low cell survival levels, 
and it has long been recognized that RBE values are larger at high 
survival levels than at low ones because of the “shoulder” on photon 
survival curves (22). For example, this is consistent with the data 
shown in Figure  2 where RBEs based on alpha ratio (generally 
reflecting high survival, low dose results) tend to be higher than 
those based on D10. Since it has been shown that photon dose–
response curves for different tumor cell types have significant 
differences [e.g., Ref. (104, 105)], one might expect that the RBE 
FiGURe 4 | RBe at 10% survival (D10) versus LeT for human tumor cell lines exposed to various charged particles heavier than protons. RBE values 
derived at 10% survival from clonogenic survival curves from all available literature are shown as a function of LET for human tumor cells exposed to (A) carbon ions; 
(B) helium ions; (C) neon ions; (D) boron ions; (e) silicon ions; and (F) argon and iron ions. The RBE values showed substantial variation at any given LET, 
independent of ion species, but in all cases the RBE increased with LET to a maximum, then decreased at high-LET levels.
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FiGURe 5 | RBe at 10% survival versus LeT for cells from various types of human tumors exposed to carbon ions. RBE values as a function of LET for 
carbon-ion beam only, calculated using D10 and sorted by tumor type, are shown. Tumor types included are: (A) brain tumor; (B) lung cancer; (C) head and neck 
squamous cell carcinoma; (D) melanoma; (e) salivary gland tumor; (F) hepatoma; (G) cervical cancer; (H) pancreatic cancer and (i) chordoma. The graphs include 
data only for LET < 100 keV/μm. The number of data points, or cell lines, varies greatly with tumor type. The slopes of the RBE versus LET curves are calculated for 
each cell line and tumor type.
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versus LET curves would also differ in a manner consistent with 
the photon sensitivity. The finding here (Figures 5 and 6) that the 
differences seem small may reflect the use of the less discriminating 
parameter, D10. If sufficient data existed to do this analysis with 
a parameter more weighted toward lower or, especially, higher 
survival levels, e.g., alpha ratio, greater differences in dependence 
of RBE on LET for various cell types might be seen.
Role of Genetic Background of Tumor 
Cells in Response to Charged Particles
In light of the proton data, discussed above, indicating a correla-
tion between cell lines with higher proton RBE values and defects 
in DNA repair, specifically in HR repair, we wondered whether 
the same finding would extend to heavier ions, notably carbon 
ions. Although the literature data on RBEs for human tumor cell 
lines shows substantial variations at any given LET, even just for 
carbon ions (Figures 2–6), we could not find any information in 
the literature on possible DNA repair deficiencies, particularly in 
HR repair, for the cell lines with the highest RBEs after carbon-ion 
irradiation, e.g., TK-1 brain tumor, Ca9–22 gingival squamous 
cell carcinoma, SQ20B head-and-neck cancer. Therefore, experi-
ments to ascertain carbon RBE values for human tumor cell lines 
known to be defective in the FA/BRCA DNA repair pathway are 
warranted. Furthermore, both the proton data of Liu et al. (44) and 
the carbon-ion data of Suzuki et al. (70) on residual unrepaired 
DNA damage (assays of 53BP1 foci and DNA damage revealed 
by PCC, respectively) suggest that such assays may be useful 
biodosimeters to select patients for charged particle therapy.
What would be the clinical application of increased tumor 
RBE values in subsets of patients? Identifying patients with 
proton- and/or heavy ion-sensitive tumors may allow us to: (a) 
de-escalate the physical dose of charged particles if normal tissue 
FiGURe 6 | RBe at 10% survival versus LeT for cells from human adenocarcinomas and squamous cell carcinomas exposed to carbon ions. RBE 
values as a function of LET for carbon ion beam only, calculated using D10 for (A) adenocarcinomas and (B) squamous cell carcinomas. The graphs show data only 
for LET < 100 keV/μm. The slopes of the curves are shown for each cell line.
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damage is a particular concern; (b) select patients for proton or 
heavy ion treatment slots who would have not otherwise had the 
opportunity to be treated with such radiations, thereby increasing 
the odds of local tumor control; or (c) biologically optimize tumor-
directed therapy, for example, by employing intensity-modulated 
ion therapy algorithms to superimpose an LET increase on the 
already pre-existing RBE advantage, thereby further improving 
local tumor control. Because RBE values tend to increase with 
increasing fractionation sensitivity of tumors (i.e., decreasing 
alpha/beta values) (42), there exists additional opportunity to 
improve the outcome of ion beam therapy in tumors with low 
alpha/beta values, such as prostate or breast cancer. However, 
this approach will require better knowledge of the inter-tumoral 
variation of alpha/beta values and the development of predictive 
biomarkers to identify appropriate tumors.
SeNSiTiviTY OF CANCeR STeM-LiKe 
CeLLS TO CHARGeD PARTiCLeS
In recent years, considerable interest has developed in the pos-
sibility that cancer stem-like cells (CSCs) in human tumors could 
be major contributors to resistance of tumors to conventional 
photon radiotherapy (RT) (106–108). However, intriguing data 
also suggest that the presence of CSCs might be overcome by 
carbon-ion therapy (89, 109). In this section, we discuss such a 
potential from a radiobiological perspective.
Cancer stem-like cells, also called cancer-initiating cells 
(CICs), are tumorigenic and have the potential to give rise to all 
cell types identified in hematological cancers and in several types 
of solid tumors (110). CSCs are regarded as “roots of cancer,” 
analogous to normal stem cells in hierarchical tissues, although 
the origin of CSCs is still not clear and various theories have 
been proposed to explain their origin (111). It is believed that 
tumor growth is driven by a discrete subpopulation of CSCs that 
are defined by their capacity for self-renewal and their ability 
to generate heterogeneous lineages of cancer cells (110). The 
CSCs can survive and usually persist in tumors for a substantial 
length of time as a distinct population and can eventually cause 
cancer recurrence after treatment and tumor metastasis. It seems 
reasonable to suggest that cancer cure can be achieved only if this 
population is eliminated.
There is growing evidence that CSCs are inherently resistant 
to conventional fractionated RT. This radioresistant phenomenon 
of CSCs has been described within the framework of the four Rs 
of radiobiology: (i) repair, (ii) redistribution, (iii) reoxygenation, 
and (iv) repopulation (112).
 (i) Regarding DNA repair, CSCs exhibit fewer DNA DSBs after 
exposure to ionizing radiation than non-tumorigenic cancer 
cells, which has been correlated with efficient DNA repair 
machinery due to constitutive hyperphosphorylation of the 
DNA checkpoint kinases Chk1 and Chk2 (106).
 (ii) Regarding redistribution, quiescent or slowly cycling cells, 
normal or cancer stem cells, generally are radioresistant, 
although dose fractionation can cause redistribution of 
radioresistant S-phase cells into a more sensitive phase of 
the cell cycle. If this happens only in tumor cells, it could 
result in a therapeutic benefit for slowly cycling normal cells, 
sparing late responding normal tissues during fractionation. 
However, if tumors also have a significant proportion of 
CSCs that are slowly cycling, any benefit from redistribution 
may not apply (112).
 (iii) Regarding reoxygenation, if the niche in which CSCs reside 
is hypoxic, during radiation fractionation the quiescent 
CSCs may be exposed to increasing oxygen levels causing 
increasing radiosensitivity due to transition of cells into an 
activated, proliferative state. It appears that in some cases, 
FiGURe 7 | A model for carbon ion-induced apoptosis and autophagy 
through the enhancement of death signals and the depression of 
survival signals. The model is based on AKT survival signaling as shown in 
our work (126). An arrow “→” indicates enhancement; a sidewise “⊣” 
indicates depression.
February 2016 | Volume 6 | Article 2311
Held et al. Charged Particles in Tumor Cells
Frontiers in Oncology | www.frontiersin.org
the CSC niche may be in perivascular regions (113, 114) 
where they may be exposed to rapidly changing cycles of 
hypoxia-reoxygenation (112). During reoxygenation, the 
cells would become more radiosensitive, and reoxygena-
tion triggers metabolic processes that generate damaging 
reactive oxygen species (ROS). However, CSCs manifest 
enhanced protection against ROS (107, 108). It was reported 
that expression of the CSC marker CD44, in particular that 
of a variant isoform (CD44v), contributes to ROS defense 
by promoting the synthesis of glutathione (GSH), a primary 
intracellular antioxidant radical scavenger (115). Hence, 
the roles of hypoxia, reoxygenation, and ROS defenses in 
CSCs appear quite complex, and more research is required 
to elucidate their roles in radiation response.
 (iv) Regarding repopulation, it was reported that developmental 
signaling pathways, such as TGF-β, Notch, Wnt/B-catenin, 
and Sonic hedgehog pathways greatly contribute to main-
tenance of CSCs, as they do with normal tissue stem cells 
(112). Intrinsic inter-conversion and dynamic equilibrium 
between CSCs and non-stem cancer cells (NSCCs) exist 
under normal and irradiation conditions, and TGF-β might 
have important roles in the equilibrium (116).
In addition to the four Rs of radiobiology, it has been shown 
that CSCs can acquire radioresistance through activation of 
anti-apoptotic Bcl-2 (117) and serine/threonine protein kinase B 
(PKB, also known as AKT) survival signaling (118, 119). Hence, 
there is substantial reason to believe that CSCs are a radiation-
resistant cell population in at least some tumors exposed to 
photon irradiation.
On the other hand, intriguing studies have reported that 
CSCs may be more effectively killed by carbon ions compared to 
photons in colon and pancreas cancers both in vitro and in vivo 
(89, 109, 120), and CSCs from colon and breast cancers may be 
more efficiently eliminated by proton irradiation than photon 
treatment, at least in  vitro (121, 122). One or more of several 
processes may explain the observations that ion beams have bio-
logical advantages for killing CSCs compared to photons. These 
include the diminished capacity for NHEJ repair, which may 
play an important role in the quiescent G0 cell cycle phase, after 
heavy ion exposure (39); a decreased OER with heavy ions (59, 
123), and an efficacy in dealing with radioresistant tumor cells 
(TP53-mutated and BCL2-overexpressing cells) (124) compared 
with results produced by photon beams. We demonstrated that 
heavy ion beams depress AKT-related survival signaling (125). 
Therefore, we speculate that heavy ion beams may target CSCs 
via depression of AKT survival signaling. Indeed, we demon-
strated that the population of CSCs is only slightly increased or 
unchanged after carbon-ion irradiation because carbon ions may 
simultaneously kill CSCs and non-CSCs, while X-rays have less 
effect on CSCs than on the bulk cancer cells (126). These results 
suggest that carbon ions may enhance apoptosis and autophagy 
through activation of death signaling and may target CSCs via 
the depression of AKT survival signaling (Figure 7). However, 
it should be noted that the observations of CSCs being prefer-
entially more sensitive to charged particles is not universal as it 
has been reported that head-and-neck cancer CSCs are resistant 
to both photon and carbon-ion irradiation (127). Clearly, more 
detailed studies are necessary, for example, using tumor samples 
from carbon- and photon-irradiated patients, to understand 
the potential significant therapeutic benefit of heavier charged 
particles on CSCs. It is also worth investigating whether, or how, 
the enhanced DNA repair advantages in CSCs might relate to the 
potential for development of biomarkers based on residual DNA 
damage for identifying patients whose cancers might be treated 
more efficaciously using charged particles, as discussed in the 
section above.
SeNSiTiviTY OF HYPOXiC TUMOR CeLLS 
TO CHARGeD PARTiCLeS
A long-recognized property of tumors is their development of 
hypoxic regions. It has also been documented, for many years, 
that hypoxic cells are resistant to photons, but that resistance 
is reduced when hypoxic cells are irradiated with higher LET 
particles (22). Suit et  al. (3) postulated that the potential gain 
from high-LET radiations in the clinic may be due principally 
to the lower OER (ratio of doses for a given endpoint in hypoxic 
to well-aerated cells). This section discusses the reduced hypoxic 
protection with carbon-ion therapy and how that might be 
exploited in cancer therapy.
Cellular sensitivity to low-LET radiations (photons, clinical 
energy protons) depends on the degree of hypoxia at the time of 
irradiation, increasing in a sigmoid fashion from an OER = 1.0 
(no difference between anoxic and well-aerated cells) at very low 
oxygen levels to a maximum (OER  ~  3.0) usually obtained by 
about 2–3% oxygen (22, 128). Sensitivity also depends on the 
duration of exposure to the hypoxic conditions. There are two 
distinct mechanisms that promote oxygen deficiency in tumor 
cells; each exposes cells to different periods of hypoxia. Acute or 
perfusion-limited hypoxia is caused by poorly formed or dysfunc-
tional vasculature that can cause transient closing of blood vessels 
that deprives the surrounding cells of an appropriate oxygen 
FiGURe 8 | The dependence of survival curves on oxygen 
concentration typically observed after exposure to X-rays and carbon 
ions. The importance of the oxygen effect is reduced with high-LET 
carbon-ion irradiation as is apparent in the small separation of the survival 
curves compared to that seen with X-rays. The large difference between the 
cell response in air and hypoxia for X-rays results in a RBEhypoxic that is greater 
than RBEoxic.
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supply (129). On the other hand, in chronic or diffusion-limited 
hypoxia, the imbalance of oxygen supply and consumption in 
actively proliferating tumor cells causes cells far from blood ves-
sels to experience a deficiency in oxygenation for long periods of 
time (130). Historically, most studies of hypoxic radioresistance 
have dealt with chronic hypoxia, but experiments investigating 
the influence of acute and chronic oxygenation conditions on cell 
response have shown increased radioresistance for the acute case 
(131–133). Ma and colleagues demonstrated that for both X-ray 
and carbon-ion irradiation, cells under acute anoxia were more 
radioresistant than those under chronic anoxia, whereas cells 
subjected to acute and chronic hypoxia (0.5% O2) exhibited no 
significant difference in sensitivity (131, 132). They argued that 
prolonged exposure to anoxia induced a breakdown in cellular 
energy metabolism, which led to delays in cell cycle progression. 
They found that cells were arrested in the G1 phase of the cell cycle 
with a significant decrease in the number of active S-phase cells 
after 24 h of hypoxia. However, abrupt changes in the oxygenation 
status did not result in changes in the cell cycle distribution. The 
energy deficiency of cells also has been associated with the reduc-
tion of DNA damage repair (133). Therefore, chronically hypoxic 
cells were found to be more vulnerable to radiation damage.
The poor performance of photons in curing hypoxic tumor 
cells has prompted researchers to turn to high-LET radiation, 
such as ion beams that have lower OERs [reviewed, e.g., in Ref. 
(22, 128, 134, 135)]. Radiation damage from low-LET beams 
is mostly mediated by free radicals (indirect effects), i.e., sec-
ondary electrons generated from the ionizations interact with 
molecules, such as water, to produce free radicals which in turn 
damage the DNA. In contrast to their low-LET counterparts, 
the contribution of radiation damage by direct ionizations in 
DNA is higher for high-LET beams. Here, the secondary elec-
trons directly interact with the critical target, thus producing, 
at least in part, different damage. Hence, the oxygen effect can 
be explained, at least in part, by differences in induction and 
repair of DNA damage. Hirayama et al. reported that the rejoin-
ing kinetics of DNA DSBs incurred from carbon-ion irradiation 
were the same for cells in oxic and hypoxic conditions (136). 
This led them to postulate that DNA DSBs produced by carbon 
ions are the same for the two oxygenation conditions. However, 
their results for X-ray irradiation showed a dependence of the 
repair dynamics on the oxygen level, with DSBs generated under 
oxic conditions rejoined more efficiently than those produced 
under hypoxia. They postulated that this resulted from differ-
ent mechanisms for DNA damage depending on oxygenation, 
namely, that in the presence of oxygen, oxygen-reacting radicals 
could cause additional DNA DSBs but in hypoxia more damage 
is produced by direct ionizations or by radicals irrelevant to 
oxygen. Furthermore, the repair times were longer after carbon-
ion irradiation and more unrepaired DNA DSBs remained after 
5 h while for X-rays almost all DSBs were efficiently rejoined. 
This can be explained by the high ionization density generated 
along the track of heavy charged particles that produces complex 
DNA damages, making repair more difficult. Therefore, the 
OER decreases with increasing LET values, with the OER of 
carbon ions about half that with X-rays. Typical survival curves 
obtained using carbon-ion and X-ray irradiation under oxic and 
hypoxic conditions are illustrated in Figure  8. The difference 
with oxygenation status is diminished with the high-LET carbon 
ions and the survival curves tend to converge. By contrast, the 
larger variation in the cell response seen for X-ray irradiation 
is reflected by the higher OER value. A consequence of the 
enhanced radioresistance observed in X-ray survival curves 
under hypoxia is that RBEhypoxic generally exceeds RBEoxic. In 
vitro studies have also shown that OER approaches unity at 
dose-averaged LETs of ~300  keV/μm (59, 134). Oxygen ions, 
with their high-LET values within therapeutic fields, might be 
advantageous for tumors with significant hypoxic fractions. 
Scifoni et al. (135) compared computed OER values in a tumor 
irradiated with oxygen or carbon ions, and showed that, assum-
ing the same dose in the entrance region, there was a dramatic 
decrease in OER for the oxygen ions.
The advantage of high-LET carbon ions over photons in 
treating tumor hypoxia has been confirmed in the clinical setting 
by Nakano et  al. (137). They measured the intratumor oxygen 
partial pressure of uterine cervical cancer patients prior to and 
at the fifth day of treatment with either photons or carbon ions 
using a polarographic electrode. The 4-year local control rates 
were found to be independent of the oxygenation condition 
for carbon-ion treatment, whereas the control rate for photon 
therapy of patients with high pO2 status was more than twice that 
with low pO2.
It has been suggested that further improvements in treatment 
outcome with carbon therapy can be achieved by considering 
the time course of reoxygenation of hypoxic areas in the tumor. 
According to Antonovic et al. (138), the number of fractions and 
the dose per fraction for carbon therapy can be optimized by tak-
ing into account the effect of local oxygenation changes on tumor 
control probability. In the future, more detailed studies are neces-
sary to take into account the OER and rates of reoxygenation in 
treatment planning for carbon-ion RT, as are underway (134, 135).
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DOSe FRACTiONATiON wiTH CHARGeD 
PARTiCLeS
Fractionated irradiation is a valuable tool in conventional RT to 
reduce early and late effects in normal tissue by allowing repair 
of sublethal damage or increase tumor response due to reoxy-
genation of a hypoxic tumor. The linear quadratic (LQ) model 
describes cell killing using single-hit and double-hit components 
(22). The shape of the curve is determined by:
 SF D e
D D( ) .= − +( )α β
2
 (1)
The α parameter describes the linear component of the 
curve, while the β component describes the quadratic portion 
of the curve. The α/β ratio, the point at which linear cell killing 
is equivalent to quadratic cell killing, is an important parameter 
used to model cell killing by radiation. Presently, this ratio is used 
as a staple for predicting the clinical effects in response to RT 
despite various limitations. A high α/β ratio, seen in many human 
tumors, suggests a predominance of the α component, implying 
a decreased response to fractionation and, therefore, clinical 
benefit from hypofractionation (decreased number of fractions 
of larger dose per fraction). A lower α/β ratio is usually associated 
with late responding normal tissue and is the basis for the thera-
peutic gain achieved using hyperfractionation (increased number 
of fractions of small dose per fraction), which allows for greater 
repair/recovery of normal tissues (139). However, some human 
tumors, e.g., prostate cancer, melanoma, and some sarcomas, may 
have α/β values similar to late responding tissues (140–142).
In image-guided RT, intensity-modulated RT, and X-ray 
stereotactic body RT (SBRT), there are tendencies to reduce the 
number of fractions and increase the dose per fraction (i.e., hypo-
fractionation) (143, 144). With carbon-ion RT, superiority of the 
physical dose distribution can lead to a reduction in the number of 
fractions (145), allowing hypofractionation. There are few relevant 
experimental data using human tumor cells on hypofractionation 
effects with high-LET charged particles. Experiments involving 
high-LET fast neutron beams demonstrated that increasing the 
dose per fraction tended to decrease the RBE for both tumor and 
normal tissues (146). However, the dose-dependent decrease in 
the RBE for the tumor was less pronounced than that for normal 
tissues, such as skin and lung (147). These experiments led to 
the assumption that the therapeutic gain of carbon-ion RT would 
increase when the dose per fraction increased. This assumption 
was confirmed in animal experiments that compared RBE for 
carbon ions between tumor and skin (148). In additional studies 
with high-LET radiation, RBE depends on dose and dose per 
fraction: dose-dependent decrease of RBE was reported after 
fast neutrons to normal skin, intestine, growing cartilage, and 
hematopoietic tissues (149), and after Ne-ions to the skin of mice 
and hamsters (150). The change in dose dependence is caused by 
the higher α/β ratio of target cells after high-LET radiation than 
after photons (151).
The value of the α term increases with increasing LET in both 
tumor and normal tissue, while the issue of whether the value of 
the β term changes with LET remains controversial (148, 152). In 
our study (153) by evaluating the therapeutic gain of carbon-ion 
fractionation using intestinal crypt survival and tumor growth 
delay (TGD) assays, the values of the α and β terms for the mouse 
fibrosarcoma (NFSa) tumor are close to those reported by Ando 
et al. (148), while those for normal tissues are different (Figure 9). 
In addition, the LET-dependent increase (e.g., slope of the regres-
sion line) of the α term for NFSa is similar to that for human 
salivary gland tumor cells (148, 154). LET-dependent increase of 
α terms for crypt is greater than that for the early skin reaction 
after daily fractionated doses to leg skin (148), whereas it is similar 
to that for the late skin reaction after 4-h interval fractionations 
to foot skin (154). These results indicate that therapeutic gain for 
carbon-ion RT depends on the normal tissue and fractionation 
schedule. Further studies with mouse skin and rat spinal cord 
where the normal tissues were exposed to varying numbers of 
fractions and doses per fraction of γ-rays and carbon ions have 
shown that the magnitude of damage repair depends on both the 
number of fractions and the size of dose per fraction for high-
LET radiation (155, 156). It was concluded that repair of radiation 
injury is much reduced with dose per fraction, especially with 
125 keV/μm carbon ions. Unfortunately, few studies of fractiona-
tion effects with carbon ions have been performed with tumors, 
especially human tumors.
As discussed above, hypoxia is one of the main factors reduc-
ing local control in some solid tumors, and fractionation in RT 
may have an advantage because of reoxygenation of the hypoxic 
areas. It has been reported that reoxygenation in several tumors 
irradiated with carbon ions occurs earlier than that in those 
irradiated with photons (157, 158). Reoxygenation in the NFSa 
fibrosarcoma was observed at 4 days, 1 day, and within 0.5 days 
after irradiation with photons, low-LET carbon ions (14 and 
18 keV/μm) and high-LET carbon ions (43, 58, and 74 keV/μm), 
respectively (157). Thus, short-term fractionated irradiation with 
carbon ions may be effective in the treatment of tumors, at least 
in part, because of altered reoxygenation.
The clinical RBE is replaced by an LET-dependent RBE for 
in vitro cell killing data determined in single-dose experiments 
and is employed to design the SOBP and in the Japanese treat-
ment planning system for carbon-ion RT (159, 160). A question 
remains as to whether the biological effects with fractionated 
doses are also uniform within the SOBP. Uzawa et al. evaluated 
uniformity of a new ridge filter that was designed based on α and 
β values for various LETs to cause mouse foot skin reaction by 
carbon-ion fractionated irradiation (154). The physical dose dis-
tribution of the new ridge filter was almost identical to the ridge 
filter designed based on in  vitro cell kill. While the LQ model 
is useful for conversion between relatively low radiation doses 
as used in conventional RT, it has been suggested that it is not 
applicable to higher fractional doses or smaller fraction numbers 
(6, 161). It has been questioned whether the LQ model is applica-
ble to hypofractionated carbon-ion RT. For establishment of the 
optimal fractionation strategy in carbon-ion RT, applicability of 
the LQ model should be investigated in future studies.
With photon RT, the rapidly expanding use of hypofractiona-
tion even to the extreme of single fractions as used in stereotactic 
radiosurgery (SRS) and SBRT has lead to recent discussion about 
whether “new” biology should be advanced to explain the greater 
than expected anti-tumor efficacy of some hypofractionation 
FiGURe 9 | α and β terms for mouse normal tissues and tumors plotted against LeT. The comparison of survival parameters of Ando et al. (red) (148) 
and our study (153) using crypt survival and tumor growth delay assays (black). The solid lines show NFSa tumor and broken lines show the normal tissues 
(crypt or skin).
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regimens. Some have proposed that consideration of only the clo-
nogenic survival of only the tumor cells is not sufficient to account 
for the observed responses [e.g., Ref. (162, 163)], although not 
all agree [e.g., Ref. (164–166)]. Brown et al. reviewed the clinical 
data for early-stage NSCLC and suggested that radiobiological 
modeling with the LQ model is adequate to explain the efficacy of 
SRS and SBRT (166). Fowler showed the potential advantages of 
hypofractionation for prostate cancer by using the LQ model and 
concluded that use of the LQ model can yield consistent results, 
for example, the remarkable agreement for tumor effects of some 
of the best schedules in regular use (167). It is likely that the same 
considerations apply to carbon-ion therapy, although few data 
exist, especially for human tumors in experimental situations. 
Here, we briefly review some aspects that may pertain.
In some situations, vascular damage may be a dominant 
pathway for tumor suppression. Irradiation of human tumor 
xenografts or rodent tumors with 5–10 Gy in a single dose causes 
relatively mild vascular damages. On the other hand, numer-
ous studies with experimental tumors indicate that irradiation 
with doses higher than 10 Gy in a single fraction or 20–60 Gy 
in limited numbers of fractions causes severe vascular damage, 
including endothelial cell apoptosis, leading to the deterioration 
of the intratumor microenvironment and indirect death of tumor 
cells (163, 168, 169). Little is known about the vascular changes 
in human tumors treated with high-dose hypofractionation, 
particularly with heavy ions, but experimentation is indicated 
to address whether radiation-induced vascular damage and the 
resulting indirect death of tumor cells may play important roles 
in the response of tumors to high-dose hypofractionation with 
charged particles.
In addition to potential vascular effects, it has been suggested 
that high-dose irradiation evokes immune reactions and thereby 
eradicates tumor cells that escaped radiation-induced death (170, 
171). In support of such notion, a recent report showed that abla-
tive RT dramatically increased T-cell priming in lymphoid tissues, 
leading to reduction/eradication of the primary tumor or distant 
metastasis in a CD8+ T-cell dependent fashion (170). Several 
studies have shown that carbon ions induce anti-tumor immunity 
(172–176), although the effects of high-LET radiation on immune 
function have not been studied in detail. Hence, enhanced immune 
reactions might be involved in the response of tumors to high-dose 
hypofractionation, especially with charged particles (177).
It is also noteworthy that, unlike photon irradiation, particle 
irradiation may suppress the metastatic potential of cancer cells 
(172, 178), and a recent paper has shown that there is a decrease in 
metastasis with decreasing fraction number of carbon ions (179). 
Clearly, further studies are warranted to gain better insights 
into the effects of high-dose hypofractionation with heavy ions 
on tumor vasculature, immune system, and metastasis, and 
how such biology might impact human tumor RBE values and 
therapeutic gain.
CONCLUSiON
In a recent review of charged particle therapy, Loeffler and Durante 
(4) stated that “Considering the current uncertainties in clinical 
results [with charged particles] and the difficulties in perform-
ing clinical trials, research in physics and radiobiology should 
reduce the cost/benefit ratio.” In this review, we have focused on 
discussion of selected aspects of radiobiological data with human 
tumors exposed to protons and heavier charged particles, raising 
specific instances where further laboratory research may contrib-
ute to improving particle therapy. With increasing understanding 
of the genetic heterogeneity in human tumors, particularly with 
regard to alterations in DNA repair pathways, a fruitful research 
area appears to be elucidation of DNA repair pathways selectively 
involved in repair of the unique clustered DNA damages caused 
by charged particles. With increases in such knowledge, the dif-
ferences can be exploited to identify patients who may be better 
treated with particles because of characteristics of their tumors 
and to develop novel pharmacologic approaches that capitalize 
on the differences in DNA damage and repair. Another area ripe 
for charged particle biology study with implications to clinical 
advances is in cancer stem cells. The intriguing observations that 
cancer stem cells from human tumors may be more effectively 
killed by carbon ions than by photons begs for further study on 
mechanisms involved – altered DNA repair? location in a hypoxic 
niche? – and consideration of how to exploit such a difference 
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to the advantage of ion therapy. Finally, the biology underlying 
the notable clinical effectiveness of high dose, hypofractionated 
charged particles, which may be explained by radiosensitivity of 
tumor cells themselves at high doses or may involve vasculature 
and/or immune system responses, requires further elucidation.
This article has focused on data from in vitro studies of human 
tumor cells, for reasons described in the Section “Introduction” 
and recognizing that there are limitations when applying in vitro 
findings to the in vivo and clinical situations. However, it is also 
clear that because of the stochastic natures of radiation-induced 
cell killing and tumor cure and the, albeit simplistic, relationship 
of the two endpoints via TCP = e−(SF × M) (where TCP is tumor 
control probability, SF is surviving fraction, and M is number 
of clonogens), understanding effects of radiations of varying 
qualities on the tumor cells themselves can be informative. The 
questions and issues raised herein require follow-up in vivo stud-
ies leading to transfer of knowledge to the clinic, but guidance 
from the in vitro work, e.g., on use of DNA damage assays and 
exploiting DNA repair as biomarkers for patient selection or 
using in vitro survival α/β information to help guide design of 
hypofractionation protocols in vivo and in the clinic, is critical.
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